Q-State Biosciences is functioning as a precision medicine company organized around care of patients having devastating genetic disorders. Q-State applies a proprietary end-to-end platform to diagnose the root cause of disease and to discover genetically targeted therapies. The firm has developed an all-optical electrophysiology platform for controlling and recording activity in electrically active cells: primary and human iPSC-derived cardiomyocytes and neurons. Combining proprietary ultrasensitive optogenetic actuators, genetically encoded voltage indicators, stem cell technology and advanced optical imaging, Q-State Biosciences uses custom instrumentation and software to probe cellular physiology with sub-micron spatial resolution and sub-millisecond temporal resolution. The firm probes dynamic cellular physiology with far higher throughput and information content than are achieved with manual patch clamp, multi electrode arrays, or calcium- or voltage-sensitive dyes. Cpincient with the firm's Series A financing in 2018, QState merged with PAirnomix and the former head of the latter took on the CEO position with QState.
